Rhythm Pharmaceuticals Inc (RYTM) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
Enrollment Completion : Completed enrollment for Phase 3 setmelanotide trial in hypothalamic obesity, with top-line data expected in 1H2025. Reimbursement Approvals : Gained reimbursement approval for IMCIVREE in Spain and Italy for Bardet-Biedl syndrome treatment. Acquisition : Acquired global rights to oral MC4R agonist LB54640 from LG Chem. Financial Guidance : Non-GAAP Operating Expenses for 2023 at $219.9 million, with 2024 projections between $250 million and $270 million. Cash Position : Sufficient funds to cover operating expenses and capital expenditure requirements into the second half of 2025. Warning! GuruFocus has detected 4 Warning Signs with RYTM. Rhythm Pharmaceuticals Inc ( NASDAQ:RYTM ), a biopharmaceutical company dedicated to developing therapies for rare diseases, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company's 8-K filing was released on February 22, 2024, detailing significant progress in bo
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.MarketBeat
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.MarketBeat
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateGlobeNewswire
RYTM
Earnings
- 5/7/24 - Miss
RYTM
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/30/24 - Form SC
- RYTM's page on the SEC website